Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 ...
Experts and guidelines recommend vesicular monoamine 2 transporter (VMAT2) inhibitors as the best option for treating more severe cases of tardive dyskinesia, an involuntary movement disorder caused ...
In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.
Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...
SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback